Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month

Journal of Clinical Laboratory Analysis

Volumn 14, Issue 3, 2000, Pages 120-124

  Magalini, Alba ^a   Puoti, Massimo ^b,c   Putzolu, Valeria ^b   Quiros Roldan, Eugenia ^b   Forleo, Maria Antonia ^b   Rossi, Stefania ^b   Zaltron, Serena ^b   Spinetti, Angiola ^b   Zanini, Barbara ^b   Zonaro, Antonella ^a   Solfrini, Roberto ^a   Carosi, Giampiero ^b  

^a OP Richiedei ^*  (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c SPEDALI CIVILI   (Italy)

Author keywords

HCV; IFN; Response; Viremia

Indexed keywords

ALPHA2A INTERFERON; INTERFERON; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KINETICS; MALE; PATIENT MONITORING; RNA ANALYSIS; TREATMENT OUTCOME; VIREMIA;

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 0034064734     PISSN: 08878013     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1098-2825(2000)14:3<120::aid-jcla6>3.0.co;2-%23     Document Type: Article

References (16)

1. EASL International Consensus Conference on Hepatitis C. J Hepatol 1999;30:956-961.
2. Davis GL. Prediction of response to interferon treatment of chronic viral hepatitis. J Hepatol 1994;21:1-3.
3. Tsubota A, Chayama K, Ikeda K, Yasuji A, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatol 1994;19:1088-1094.
4. Yoshioka K, Kakumu S, Wakita T, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of HCV. Hepatol 1992; 16:293-299.
5. Lam NP, Neuman A, Gretch D, Wiley T, Perelson A, Layden T. Dosedependent acute clearance of hepatitis C genotype 1 virus with interferon alpha. Hepatology 1997;26:226-231.
6. Idilman R, De Maria N, Colantoni A, Dokmeci A, Van Thiel DH. Interferon treatment of cirrhosis patients with chronic hepatitis C. J Viral Hepatitis 1997;4:81-91.
7. Gavier B, Martinez-Gonzalez MA, Riezu-Boj JI, et al. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology 1997;113:1647-1653.
8. Neuman AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-107.
9. Dusheiko GM, Zuckerman AJ. Treatment of chronic viral hepatitis. J Antimicrob Chemother 1993;32:107-120.
10. Fried MW, Hoofnage JH. Therapy of hepatitis C. Semin Liver Dis 1995;15:82-91.
11. Taylor D, Shi S, Romano P, Barber G, Lai M. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999;285:107-110.
12. Yamamoto C, Enomoto N, Kurosaki M, et al. Nucleotide sequence variations in the Internal Ribosome Entry Site of hepatitis C virus-1b: no association with efficacy of interferon therapy or serum HCV-RNA levels. Hepatology 1997;26:1616-1620.
13. Rispeter K, Lu M, Wiese M, et al. The "interferon sensitivity determining region" of hepatitis C virus is a stable sequence element. J Hepatol 1998;29:352-361.
14. Khorsi H, Castelain S, Wyseur A, et al. Mutations of hepatitis C virus 1b NS5S 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alpha therapy in French patients. J Hepatol 1997;27:72-77.
15. McHutchison J, Gordon S, Schif E, et al. Interferon alpha-2 alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
16. Davis G, Esteban R, Rustgi V, et al. Interferon alpha-2a alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-1499.